The Challenge of Pain Management in Patients With Myasthenia Gravis

REFERENCES

• Thanvi B R, Lo T C. Update on myasthenia gravis. Postgrad Med J 2004; 80: 690–700
   PubMed Web of Science ®Google Scholar
• Romi F, Gilhus N E, Aarli J A. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand 2005; 111: 134–141
   PubMed Web of Science ®Google Scholar
• Hughes B W, Moro De Casillas M L, Kaminski H J. Pathophysiology of myasthenia gravis. Semin Neurol 2004; 24: 21–30
   Google Scholar
• Drachman D B. Myasthenia gravis. N Engl J Med Jun 23, 1994; 330(25)1797–1810
   PubMed Web of Science ®Google Scholar
• Lindstrom J M, Seybold M E, Lennon V A, Whittingham S, Duane D D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054–1059
   PubMed Web of Science ®Google Scholar
• Vincent A, Leite M I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005; 18: 519–525
   PubMed Web of Science ®Google Scholar
• Cahoon W D, Jr, Kockler D R. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother 2006; 40: 295–298
   Google Scholar
• Prakash K M, Ratnagopal P, Puvanendran K, Lo Y L. Mycophenolate mofetil—as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: the Singapore experience. J Clin Neurosci 2007; 14: 278–281
   Google Scholar
• Tada M, Shimohata T, Tada M, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci 2006; 247: 17–20
   Google Scholar
• Ponseti J M, Azem J, Fort J M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005; 64: 1641–1643
   PubMed Web of Science ®Google Scholar
• Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006; 33: 575–580
   PubMed Web of Science ®Google Scholar
• Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol Sep 15, 2008; 201–202: 90–94
   PubMed Web of Science ®Google Scholar
• Rowin J, Meriggioli M N, Tuzun E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004; 63: 2390–2392
   PubMed Web of Science ®Google Scholar
• Rowin J. Etanercept treatment in myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 300–304
   Google Scholar
• Taiuti R, Avanzi G, Paoletti P, Marconi G. Plasma-exchange in myasthenia gravis: a study in 20 patients. Int J Artif Organs 1988; 11: 308–312
   Google Scholar
• Pinching A J, Peters D K. Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2: 1373–1376
   PubMed Web of Science ®Google Scholar
• Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000; 23: 551–555
   PubMed Web of Science ®Google Scholar
• Kalso E, Mennander S, Tasmuth T, Nilsson E. Chronic post-sternotomy pain. Acta Anaesthesiol Scand 2001; 45: 935–939
   PubMed Web of Science ®Google Scholar
• Kost R G, Straus S E. Postherpetic neuralgia—pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32–42
   PubMed Web of Science ®Google Scholar
• Gupta G, Lautenbach E, Lewis J D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483–1490
   PubMed Web of Science ®Google Scholar
• Samtleben W, Mistry-Burchardi N, Hartmann B, Lennertz A, Bosch T. Therapeutic plasma exchange in the intensive care setting. Ther Apher 2001; 5: 351–357
   Google Scholar
• Piper J M, Ray W A, Daugherty J R, Griffin M R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735–740
   PubMed Web of Science ®Google Scholar
• Griffin M R, Piper J M, Daugherty J R, Snowden M, Ray W A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257–263
   PubMed Web of Science ®Google Scholar
• Harris K P, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine. A potentially serious adverse interaction. Transplantation 1988; 46: 598–599
   Google Scholar
• Branthwaite J P, Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis. Lancet 1991; 337: 252
   Google Scholar
• Deray G, Le Hoang P, Aupetit B, Achour A, Rottembourg J, Baumelou A. Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol 1987; 27: 213–214
   Google Scholar
• Krause I, Cleper R, Eisenstein B, Davidovits M. Acute renal failure, associated with non-steroidal anti-inflammatory drugs in healthy children. Pediatr Nephrol 2005; 20: 1295–1298
   PubMed Web of Science ®Google Scholar
• Sanchez de la Nieta M D, Rivera F, De la Torre M, et al. Acute renal failure and oligohydramnios induced by magnesium dypirone (metamizol) in a pregnant woman. Nephrol Dial Transplant 2003; 18: 1679–1680
   PubMedGoogle Scholar
• Perneger T V, Whelton P K, Klag M J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675–1679
   PubMed Web of Science ®Google Scholar
• Abel M, Eisenkraft J B. Anesthetic implications of myasthenia gravis. Mt Sinai J Med 2002; 69: 31–37
   PubMed Web of Science ®Google Scholar
• Bjornsson T D, Callaghan J T, Einolf H J, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443–469
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N. Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). Pain Med 2006; 7: 164–165
   Google Scholar
• Sharom F J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105–127
   PubMed Web of Science ®Google Scholar
• Syvanen S, Hooker A, Rahman O, et al. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci Dec, 2008; 97(12)5386–5400
   Google Scholar
• Rodriguez M, Ortega I, Soengas I, Suarez E, Lukas J C, Calvo R. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol 2004; 56: 367–374
   PubMed Web of Science ®Google Scholar
• Letrent S P, Pollack G M, Brouwer K R, Brouwer K L. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 1999; 27: 827–834
   PubMed Web of Science ®Google Scholar
• Suzuki T, Zaima C, Moriki Y, Fukami T, Tomono K. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. J Drug Target 2007; 15: 67–74
   PubMed Web of Science ®Google Scholar
• Bostrom E, Simonsson U S, Hammarlund-Udenaes M. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 2005; 94: 1060–1066
   PubMed Web of Science ®Google Scholar
• Watson C P, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166–1171
   PubMed Web of Science ®Google Scholar
• Max M B, Lynch S A, Muir J, Shoaf S E, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250–1256
   PubMed Web of Science ®Google Scholar
• Howard J F, Jr. Adverse drug effects on neuromuscular transmission. Semin Neurol 1990; 10: 89–102
   Google Scholar
• Gilron I, Watson C P, Cahill C M, Moulin D E. Neuropathic pain: a practical guide for the clinician. CMAJ 2006; 175: 265–275
   PubMed Web of Science ®Google Scholar
• Scheschonka A, Beuche W. Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. Pain 2003; 104: 423–424
   Web of Science ®Google Scholar
• Boneva N, Brenner T, Argov Z. Gabapentin may be hazardous in myasthenia gravis. Muscle Nerve 2000; 23: 1204–1208
   Web of Science ®Google Scholar
• Sindrup S H, Jensen T S. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18: 22–27
   PubMed Web of Science ®Google Scholar
• Kurian M A, King M D. Antibody positive myasthenia gravis following treatment with carbamazepine–a chance association?. Neuropediatrics 2003; 34: 276–277
   Google Scholar
• Rasmussen M. Carbamazepine and myasthenia gravis. Neuropediatrics 2004; 35: 259
   Google Scholar
• Zaidat O O, Kaminski H J, Berenson F, Katirji B. Neuromuscular transmission defect caused by carbamazepine. Muscle Nerve 1999; 22: 1293–1296
   PubMed Web of Science ®Google Scholar
• Soto Alvarez J, Sacristan Del Castillo J A, Alsar Ortiz M J. Effect of carbamazepine on cyclosporin blood level. Nephron 1991; 58: 235–236
   Google Scholar
• Yee G C, McGuire T R. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet 1990; 19: 319–332
   PubMed Web of Science ®Google Scholar
• Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. Biomed Pharmacother 1986; 40: 301–308
   PubMed Web of Science ®Google Scholar
• Privitera M R, Greden J F, Gardner R W, Ritchie J C, Carroll B J. Interference by carbamazepine with the dexamethasone suppression test. Biol Psychiatry 1982; 17: 611–620
   Google Scholar
• Evers S. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 2008; 9: 2565–2573
   PubMed Web of Science ®Google Scholar
• Cahana A, Shvelzon V, Dolberg O, Magora F, Shir Y. [Intravenous lignocaine for chronic pain: an 18-month experience]. Harefuah 1998; 134: 692–694; 751, 750
   Google Scholar
• Zin C S, Nissen L M, Smith M T, O'Callaghan J P, Moore B J. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008; 22: 417–442
   PubMed Web of Science ®Google Scholar
• Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151–158
   PubMed Web of Science ®Google Scholar
• Gammaitoni A R, Alvarez N A, Galer B S. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002; 59: 2215–2220
   PubMed Web of Science ®Google Scholar
• http://www.qtdrugs.org(ArizonaCERT) TUoACfEaRoT. QT drug list. Accessed September 15, 2008
   Google Scholar
• Challapalli V, Tremont-Lukats I W, McNicol E D, Lau J, Carr D B. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005, (4):CD003345
   Google Scholar
• Ando K, Wallace M S, Braun J, Schulteis G. Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000; 25: 468–474
   PubMedGoogle Scholar
• Tauzin-Fin P, Sesay M, Delort-Laval S, Krol-Houdek M C, Maurette P. Intravenous magnesium sulphate decreases postoperative tramadol requirement after radical prostatectomy. Eur J Anaesthesiol 2006; 23: 1055–1059
   Google Scholar
• Mauskop A, Altura B T, Cracco R Q, Altura B M. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 1996; 36: 154–160
   PubMed Web of Science ®Google Scholar
• Frank L R, Olson C M, Shuler K B, Gharib S F. Intravenous magnesium for acute benign headache in the emergency department: a randomized double-blind placebo-controlled trial. CJEM 2004; 6: 327–332
   Google Scholar
• Bashuk R G, Krendel D A. Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve 1990; 13: 708–712
   PubMedGoogle Scholar
• Mueksch J N, Stevens W A. Undiagnosed myasthenia gravis masquerading as eclampsia. Int J Obstet Anesth 2007; 16: 379–382
   PubMed Web of Science ®Google Scholar
• Catanzarite V A, McHargue A M, Sandberg E C, Dyson D C. Respiratory arrest during therapy for premature labor in a patient with myasthenia gravis. Obstet Gynecol 1984; 64: 819–822
   Google Scholar
• Dillon F X. Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 2004; 24: 83–94
   Google Scholar
• Molenaar P C, Van Kempen G T. Effect of diazepam on muscle weakness in a model of myasthenia gravis in rats. J Neural Transm Gen Sect 1993; 93: 181–185
   Google Scholar
• Ochs G, Struppler A, Meyerson B A, et al. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry 1989; 52: 933–939
   PubMedGoogle Scholar
• Akpolat N, Tilgen H, Gursoy F, Saydam S, Gurel A. Thoracic epidural anaesthesia and analgesia with bupivacaine for transsternal thymectomy for myasthenia gravis. Eur J Anaesthesiol 1997; 14: 220–223
   Google Scholar
• Kawamata M, Miyabe M, Nakae Y, et al. [Continuous thoracic epidural blockade in combination with general anesthesia with nitrous oxide, oxygen, and sevoflurane in two patients with myasthenia gravis]. Masui 1993; 42: 898–901
   Google Scholar
• Mallinckrodt I. Morphine sulfate extended-release tablets package insert. St. Louis, MO 2003
   Google Scholar
• Skye Pharma I. DepoDur™ (morphine sulfate extended-release liposome injection) package insert. San Diego, CA 2004
   Google Scholar
• Novartis P C. Sandimmune® (cyclosporine) package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ 2002
   Google Scholar
• Hansten P D, Horn J R. Cytochrome P450 Enzymes and Drug Interactions, Table of Cytochrome P450 Substrates, Inhibitors, Inducers and P-glycoprotein, with Footnotes. 2008 Edition. H&H Publications, Freeland, WAUSA 2008
   Google Scholar
• Ejendal K F, Hrycyna C A. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 2005; 67: 902–911
   PubMed Web of Science ®Google Scholar
• Edelman J, Potter J M, Hackett L P. The effect of intra-articular steroids on plasma salicylate concentrations. Br J Clin Pharmacol 1986; 21: 301–307
   PubMed Web of Science ®Google Scholar
• Graham G G, Champion G D, Day R O, Paull P D. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther 1977; 22: 410–420
   PubMed Web of Science ®Google Scholar
• Miners J O. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17: 327–344
   PubMed Web of Science ®Google Scholar
• Parke-Davis Division W LC. Product Information: Easprin(R), aspirin tablets. Morris Plains, NJ 1996
   Google Scholar
• Gabriel S E, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787–796
   PubMed Web of Science ®Google Scholar
• Sheiner P A, Mor E, Chodoff L, et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1994; 57: 1132–1133
   Google Scholar
• Merck & Co. I. Vioxx® (rofecoxib) package insert. Whitehouse Station, NJ 2004
   Google Scholar
• Novartis. Myfortic® (mycophenolate sodium) package insert. East Hanover, NJ 2007
   Google Scholar
• Roche-Pharmaceuticals. CellCept® (mycophenolate mofetil) package insert. Nutley, NJ 2007
   Google Scholar
• Clinical Pharmacology [database online]. 2008, http://cp.gsm.com Updated Last Updated Date. Accessed September 1, 2008
   Google Scholar
• Agar J W. Cyclosporin A and mefenamic acid in a renal transplant patient. Aust N Z J Med 1991; 21: 784–785
   PubMedGoogle Scholar
• Altman R D, Perez G O, Sfakianakis G N. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992; 93: 396–402
   Google Scholar
• Constantopoulos A. Colitis induced by interaction of cyclosporine A and non-steroidal anti-inflammatory drugs. Pediatr Int 1999; 41: 184–186
   Google Scholar
• Kovarik J M, Kurki P, Mueller E, et al. Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. J Rheumatol 1996; 23: 2033–2038
   PubMed Web of Science ®Google Scholar
• Sesin G P, O'Keefe E, Roberto P. Sulindac-induced elevation of serum cyclosporine concentration. Clin Pharm 1989; 8: 445–446
   Google Scholar
• Sturrock N D, Lang C C, Struthers A D. Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens 1994; 12: 919–924
   Google Scholar
• Tugwell P, Ludwin D, Gent M, et al. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 1997; 24: 1122–1125
   PubMed Web of Science ®Google Scholar
• Wyeth-Pharmaceuticals I. Product Information: LODINE(R) etodolac oral capsule, oral tablet. Philadelphia, PA 2005
   Google Scholar
• Adams S L, Mathews J, Grammer L C. Drugs that may exacerbate myasthenia gravis. Ann Emerg Med 1984; 13: 532–538
   Google Scholar
• Finkel A G, Howard J F, Jr, Mann J D. Successful treatment of headache related to intravenous immunoglobulin with antimigraine medications. Headache 1998; 38: 317–321
   Google Scholar
• Astellas Pharm US I. Product Information: PROGRAF(R) tacrolimus oral capsules, IV injection. Deerfield, IL 2006
   Google Scholar
• Drug-induced Myasthenia Gravis. Thomson Micromedex, Greenwood Village, ColoradoUSA 1974–2008, Updated Last Updated Date. Accessed September 1, 2008
   Google Scholar
• Schwarz Pharma. Product Information: NIRAVAM(TM) alprazolam orally disintegrating tablet. Milwaukee, WI 2003
   Google Scholar
• Scott D B, Lee A, Fagan D, Bowler G M, Bloomfield P, Lundh R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–569
   PubMed Web of Science ®Google Scholar
• Bruckner J, Thomas K C, Jr, Bikhazi G B, Foldes F F. Neuromuscular drug interactions of clinical importance. Anesth Analg 1980; 59: 678–682
   Google Scholar
• Olsen G D. Methadone binding to human plasma proteins. Clin Pharmacol Ther 1973; 14: 338–343
   PubMed Web of Science ®Google Scholar
• Inturrisi C E, Colburn W A, Kaiko R F, Houde R W, Foley K M. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392–401
   PubMed Web of Science ®Google Scholar
• Halliburton J R. The pharmacokinetics of fentanyl, sufentanil and alfentanil: a comparative review. AANA J 1988; 56: 229–233
   Google Scholar
• Thamdrup B, Ostergaard O V, Clausen E. Plasma exchange in the treatment of propoxyphene intoxications. Int J Clin Pharmacol Ther Toxicol 1986; 24: 379–380
   PubMedGoogle Scholar
• Bullingham R E, McQuay H J, Moore A, Bennett M R. Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28: 667–672
   PubMed Web of Science ®Google Scholar
• Fauvelle F, Leon A, Niakate M T, Petitjean O, Guillevin L. Pharmacokinetics of paracetamol, diclofenac and vidarabine during plasma exchange. Int J Artif Organs 1988; 11: 195–200
   Google Scholar
• Jensen S, Glud T K, Bacher T, Ersgaard H. Ibuprofen-induced meningitis in a male with systemic lupus erythematosus. Acta Med Scand 1987; 221: 509–511
   PubMed Web of Science ®Google Scholar
• Walson P D, Mortensen M E. Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children. Clin Pharmacokinet 1989; 17(Suppl 1)116–137
   Google Scholar
• Martina S D, Vesta K S, Ripley T L. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39: 854–862
   PubMed Web of Science ®Google Scholar
• Nenov V D, Marinov P, Sabeva J, Nenov D S. Current applications of plasmapheresis in clinical toxicology. Nephrol Dial Transplant 2003; 18(Suppl 5)v56–v58
   Google Scholar
• Vollmer K O, von Hodenberg A, Kolle E U. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986; 36: 830–839
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen S I, Kupferberg H J, Levy R H, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001; 43: 11–58
   PubMed Web of Science ®Google Scholar
• Czuczwar S J, Patsalos P N. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001; 15: 339–350
   PubMed Web of Science ®Google Scholar
• Gambi D, Oggioni R, Mangani V, Librenti M, Manescalchi F, Tulli G. [Acute carbamazepine poisoning treated with plasmapheresis. Description of a clinical case]. Minerva Anestesiol 1993; 59: 547–552
   Google Scholar
• Duzova A, Baskin E, Usta Y, Ozen S. Carbamazepine poisoning: treatment with plasma exchange. Hum Exp Toxicol 2001; 20: 175–177
   PubMed Web of Science ®Google Scholar
• Siddiqi Z A, Holt A, Ahmed S N. Effect of plasma exchange on carbamazepine levels in a patient with myasthenia gravis and epilepsy. Epilepsia 2005; 46: 1841–1842
   PubMed Web of Science ®Google Scholar
• Puentes E, Puzantian T, Lum B L. Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. Ther Drug Monit 1999; 21: 351–354
   Google Scholar
• Lai C W, Leppik I E, Jenkins D C, Sood P. Epilepsy, myasthenia gravis, and effect of plasmapheresis on antiepileptic drug concentrations. Arch Neurol 1990; 47: 66–68
   PubMed Web of Science ®Google Scholar
• Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31: 29–46
   PubMed Web of Science ®Google Scholar
• Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993; 24: 441–452
   PubMed Web of Science ®Google Scholar
• Labbe L, Turgeon J. Clinical pharmacokinetics of mexiletine. Clin Pharmacokinet 1999; 37: 361–384
   PubMed Web of Science ®Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006; 80: 203–215
   PubMed Web of Science ®Google Scholar
• Berlin A, Dahlstrom H. Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration. Eur J Clin Pharmacol 1975; 9: 155–159
   PubMed Web of Science ®Google Scholar
• Crevoisier C, Delisle M C, Joseph I, Foletti G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol 2003; 49: 173–177
   PubMed Web of Science ®Google Scholar
• Greenblatt D J, Abernethy D R, Locniskar A, Harmatz J S, Limjuco R A, Shader R I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27–35
   PubMed Web of Science ®Google Scholar
• Vinik H R, Reves J G, Greenblatt D J, Abernethy D R, Smith L R. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 1983; 59: 390–394
   PubMed Web of Science ®Google Scholar
• Wuis E W, Dirks M J, Vree T B, Van der Kleijn E. Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses. Pharm Weekbl Sci 1990; 12: 71–74
   Google Scholar
• Kochak G M, Rakhit A, Wagner W E, Honc F, Waldes L, Kershaw R A. The pharmacokinetics of baclofen derived from intestinal infusion. Clin Pharmacol Ther 1985; 38: 251–257
   PubMed Web of Science ®Google Scholar